Trial reportJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2015
The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 72 citations in OpenAlex.
- Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer.Translational psychiatry · 2022Trial
- PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders.Translational psychiatry · 2026Review
- Quantification of [Frontiers in neuroscience · 2026Article
- The Role of Fatty Acid Amide Hydrolase, a Key Regulatory Endocannabinoid Enzyme, in Domain-Specific Cognitive Performance in Psychosis.Schizophrenia bulletin · 2025Article
- A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use.Drug and alcohol dependence reports · 2025Article
- Fatty acid amide hydrolase in major depressive episodes: A [Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.Biomolecules · 2025Review
- Plasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls.International journal of molecular sciences · 2023Article
- Review
- Endocannabinoid System Biomarkers in Alzheimer's Disease.Cannabis and cannabinoid research · 2023Article
- In vivo brain endocannabinoid metabolism is related to hippocampus glutamate and structure - a multimodal imaging study with PET,Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Acquisition of threat responses are associated with elevated plasma concentration of endocannabinoids in male humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Fatty acid amide hydrolase levels in brain linked with threat-related amygdala activation.Neuroimage. Reports · 2022Article
- The role of cannabinoids in shaping lifespan neurodevelopment.Journal of neuroscience research · 2022Article
- A common genetic variant in fatty acid amide hydrolase is linked to alterations in fear extinction neural circuitry in a racially diverse, nonclinical sample of adults.Journal of neuroscience research · 2022Article
- Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation?Biological psychiatry · 2022Review
- Higher trait neuroticism is associated with greater fatty acid amide hydrolase binding in borderline and antisocial personality disorders.Scientific reports · 2022Observational
- The role of endocannabinoids in consolidation, retrieval, reconsolidation, and extinction of fear memory.Pharmacological reports : PR · 2021Review
- Fatty acid amide hydrolase binding is inversely correlated with amygdalar functional connectivity: a combined positron emission tomography and magnetic resonance imaging study in healthy individuals.Journal of psychiatry & neuroscience : JPN · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Isabelle Boileau1] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Human Brain Lab, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [4] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [5] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [6] Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Rachel F Tyndale1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [3] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Belinda Williams1] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Human Brain Lab, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [4] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Esmaeil Mansouri1] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Human Brain Lab, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [4] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Duncan J Westwood1] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Human Brain Lab, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [4] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [5] Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Bernard Le Foll1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [3] Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada [4] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Pablo M Rusjan1] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Romina Mizrahi1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [4] Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Vincenzo De Luca1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [3] Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Qian ZhouDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Alan A Wilson1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Sylvain Houle1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Stephen J Kish1] Human Brain Lab, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [4] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [5] Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada [6] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Junchao Tong1] Human Brain Lab, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [3] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [4] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Centre for Addiction and Mental Health · CAUniversity of Toronto · CA
Funding
Endocannabinoid Metabolism in Cannabis Users: PET Studies with the Novel Probe [1R21DA036024 · NIDA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI BOILEAU, ISABELLE · 2013 to 2014
$295kCognitive and Behavioral Effects of Sleep Restriction in Adolescents with ADHDR03MH109787 · NIMH · CINCINNATI CHILDRENS HOSP MED CTR · PI BECKER, STEPHEN P · 2016 to 2017
$156kCanadian Institutes of Health Research TMH109787NIDA NIH HHS R21 DA036024NIMH NIH HHS R03 MH109787
Abstract
The common functional single-nucleotide polymorphism (rs324420, C385A) of the endocannabinoid inactivating enzyme fatty acid amide hydrolase (FAAH) has been associated with anxiety disorder relevant phenotype and risk for addictions. Here, we tested whether the FAAH polymorphism affects in vivo binding of the FAAH positron emission tomography (PET) probe [(11)C]CURB ([(11)C-carbonyl]-6-hydroxy-[1,10-biphenyl]-3-yl cyclohexylcarbamate (URB694)). Participants (n=24) completed one [(11)C]CURB/PET scan and were genotyped for rs324420. Relative to C/C (58%), A-allele carriers (42%) had 23% lower [(11)C]CURB binding (λk3) in brain. We report evidence that the genetic variant rs324420 in FAAH is associated with measurable differences in brain FAAH binding as per PET [(11)C]CURB measurement.
Indexed as
AllelesAmidohydrolasesAnxiety DisordersPolymorphism, Single NucleotidePositron-Emission TomographyRadiopharmaceuticalsAdultFatty Acid Amide HydrolasesFemaleHumansMaleMiddle AgedRadiographyAmidohydrolasesFatty Acid Amide HydrolasesRadiopharmaceuticals
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.